GT-307

N/A

Report date: 2026/04/28 20:00:22

Base Information

Drug NameGT-307
Drug Alias NameGT-307
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating LymphocytesCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas12 > CRISPR-Cas12b
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaClinical
Originator Companiesshenzhen Grit Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active Companiesshenzhen Grit Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsColorectal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A